Unlike many other markets where sunscreens are regulated as cosmetics, in the U.S. they are legally classified as over-the-counter (OTC) drugs because they are intended to prevent sunburn and reduce the risk of skin cancer and premature skin aging caused by ultraviolet radiation.

In March 2026, the Government of Canada published a new framework for the risk assessment of nanomaterials under the Canadian Environmental Protection Act (CEPA).

The state of New Jersey has taken a firm step in regulating persistent chemicals with the passage of law S1042 – Protecting Against Forever Chemicals Act, in effect since January 12, 2026. Within this regulation, the cosmetics sector faces a significant change: the marketing of products containing intentionally added PFAS will be prohibited from January 12, 2028.

The regulation of fragrance allergens in cosmetic products has evolved in recent years in multiple jurisdictions. Following updates introduced in the European Union and the growing interest in improving the information available to consumers, Canada has also incorporated new regulatory requirements regarding transparency on fragrance allergens.

This article explains the key differences and what companies should consider when adapting EU or UK safety documentation for the United States.

La U.S. Food and Drug Administration (FDA) ha publicado los fees aplicables para el año fiscal 2026 dentro del programa OMUFA (Over-the-Counter Monograph Drug User Fee Program), que afectan tanto a las instalaciones que fabrican medicamentos OTC bajo monografía como a las empresas que soliciten modificaciones en una monografía existente.